Wiener Privatklinik
Wiener Privatklinik
Austria, Vienna
Christoph Zielinski
44 anni di esperienza
accreditamenti :
Clinica certificata da :
| Turchia | Austria | Spagna | |
| Resezione dell'intestino tenue | da $12,150 | da $25,000 | da $18,000 |
| Radioterapia per il cancro intestinale | da $5,800 | da $6,971 | da $4,066 |
| Radioterapia per il cancro colorettale | da $7,000 | da $12,000 | da $10,000 |
| Chemioterapia per carcinoma mammario | da $1,200 | da $15,000 | da $3,500 |
| Chemioterapia Intraperitoneale Ipertermica (HIPEC) | da $22,500 | da $40,000 | da $25,000 |
Il medico è un distinto oncologo medico e internista austriaco con oltre due decenni di esperienza, specializzato in cancro al seno, neoplasie ginecologiche e terapie mirate contro il cancro. Laureato all'Università di Vienna, il medico ha completato la residenza in medicina interna e oncologia medica presso l'Università Medica di Vienna. Il medico ha contribuito ai primi studi clinici sulle terapie mirate ed è un'autorità leader nel trattamento personalizzato del cancro.<\/p>
Attualmente serve come consulente senior presso il Wiener Privatklinik e continua il lavoro accademico presso l'Università Medica di Vienna, il medico si concentra sulla terapia sistemica individualizzata del cancro, l'immunoterapia e la ricerca oncologica traslazionale. La ricerca del medico include lo sviluppo di biomarcatori e meccanismi di resistenza ai farmaci mirati, con pubblicazioni su riviste internazionali di spicco.<\/p>
Il medico è una figura di spicco nell'oncologia medica, ematologia e immunoterapia del cancro, con una carriera che si estende per oltre quattro decenni. Dopo aver conseguito una laurea in medicina presso l'Università di Vienna negli anni '70, il medico ha completato la formazione specialistica in medicina interna e oncologia negli anni '80.<\/p>
Negli anni '90, il medico è stato nominato capo della Divisione Clinica di Oncologia presso l'Università Medica di Vienna, guidando il più grande dipartimento di oncologia dell'Austria. Gli anni 2000 hanno visto la fondazione del Centro Oncologico Integrato di Vienna, integrando assistenza ai pazienti, ricerca e istruzione.<\/p>
Il medico ha servito come Presidente del Gruppo Cooperativo Oncologico dell'Europa Centrale negli anni 2010 e attualmente ricopre le posizioni di Presidente del Centro Oncologico di Vienna e Direttore Medico del Centro Internazionale di Oncologia della Wiener Privatklinik.<\/p>
Il medico ha completato gli studi di medicina presso l'Università di Vienna nel 1998, con formazione presso UCLA e l'Università della Pennsylvania. Dal 2000 al 2006, il medico si è formato come specialista in medicina interna presso l'Ospedale Generale di Vienna, seguito da una specializzazione aggiuntiva in gastroenterologia ed epatologia dal 2006 al 2008, e in medicina intensiva interna dal 2008 al 2010.<\/p>
Nel 2003, il medico ha fondato e gestito il laboratorio di emodinamica epatica e la clinica ambulatoriale per la cirrosi presso l'Università Medica di Vienna. Dal 2018, il medico è a capo del Dipartimento di Medicina Interna I presso l'Ospedale dei Fratelli della Misericordia di Vienna.<\/p>
Treatment for small intestine cancer in Austria centers on surgical resection combined with systemic therapies like chemotherapy and immunotherapy. Leading Viennese private hospitals utilize multidisciplinary oncology boards. Treatments follow European Society for Medical Oncology guidelines. Personalized protocols often include targeted drugs for specific genetic mutations or histotypes.
Bookimed Expert Insight: Advanced oncology care in Vienna is highly concentrated. Wiener Privatklinik and Döbling Private Hospital provide access to professors from the Medical University of Vienna. These specialists often lead early clinical trials for targeted therapies. This means patients receive treatment from the same experts who develop international protocols. Döbling Private Hospital also maintains complication rates significantly below international nominal values.
Patient Consensus: Many emphasize getting a second opinion from a multidisciplinary tumor board for this rare diagnosis. After surgery, patients often note that dietary support is vital for managing recovery-related weight loss.
Austria ranks among the top 10 global healthcare systems, offering elite standards for small intestine cancer care. Medical centers in Vienna provide advanced multidisciplinary treatments. These include precision medicine, immunotherapy, and complex procedures like Hyperthermic Intraperitoneal Chemotherapy. Facilities maintain rigorous International Organization for Standardization (ISO) certifications.
Bookimed Expert Insight: While many countries offer general oncology, Austria focuses on centralized expertise within private-public partnerships. For example, Amethyst Radiotherapy Austria operates directly within Wiener Privatklinik. This creates a one-stop hub where specialized radiation and surgical oncology teams collaborate daily. This integration can significantly reduce the time between diagnosis and the start of treatment.
Patient Consensus: Patients note that receiving care at centers that utilize multidisciplinary tumor boards is essential for rare gastrointestinal cancers. They emphasize the importance of confirming that surgeons have specific experience with duodenal or small bowel tumors before proceeding.
Austria treats small intestine cancer at specialized university hospitals and private clinics in Vienna and Innsbruck. These centers utilize multidisciplinary tumor boards and advanced visceral surgery. Facilities like Wiener Privatklinik and AKH Vienna offer specialized resection and targeted oncology protocols.
Bookimed Expert Insight: Choosing a hospital in Vienna like Wiener Privatklinik provides unique access to academic expertise. Over 400 physicians work there. Many are also professors at the Medical University of Vienna. This structure allows patients to receive private care from researchers who develop the latest protocols. This specific link between private facilities and university research is a hallmark of Austrian oncology care.
Patient Consensus: Patients emphasize finding a major university hospital with a multidisciplinary team for rare tumors. They note that having pathologies re-reviewed by experienced academic centers ensures the most accurate treatment plan.
Qualified Austrian oncologists for small intestine cancer must be board-certified in internal medicine and medical oncology. Prioritize specialists at university-affiliated clinics who lead multidisciplinary tumor boards. These experts should demonstrate expertise in targeted therapies and molecular genetic testing for rare gastrointestinal malignancies.
Bookimed Expert Insight: Austrian oncology is unique because top university professors often consult at private facilities like Wiener Privatklinik. This allows patients to access academic-level expertise in a private hospital setting with 130 beds. You get university-grade treatment protocols without the typical wait times of public research institutions.
Patient Consensus: Patients emphasize finding a doctor who distinguishes between small-bowel adenocarcinoma and neuroendocrine tumors. They note it is important to choose specialists who coordinate closely with surgeons and radiologists.
International patients are legally eligible for small intestine cancer clinical trials in Austria. EU Regulation 536/2014 permits enrollment regardless of nationality. Acceptance depends on meeting specific medical criteria. Patients must also manage complex administrative, linguistic, and financial requirements for cross-border participation.
Bookimed Expert Insight: Clinical trials for rare gastrointestinal cancers often require specific molecular markers. Univ. Prof. Dr. Wolfgang Köstler at Wiener Privatklinik specializes in individualized cancer treatments and targeted therapies. His research focus on resistance mechanisms suggests that patients with rare small intestine tumors should prioritize centers with strong biomarker-driven protocols over those using generic site-specific approaches. This targeted focus may improve eligibility for basket trials that accept various solid tumors based on genetic mutations rather than just primary organ site.
Patient Consensus: Patients find that having original pathology slides and molecular reports ready for re-review prevents major delays. They emphasize that while the experimental drug is free, the logistics and frequent travel visits are the hardest part to manage.